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Combined Population Dynamics 
and Entropy Modelling Supports 
Patient Stratification in Chronic 
Myeloid Leukemia
Marc Brehme1,*, Steffen Koschmieder2,*, Maryam Montazeri1, Mhairi Copland3, 
Vivian G. Oehler4, Jerald P. Radich4, Tim H. Brümmendorf2,* & Andreas Schuppert1,5,*
Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer 
progression, biomarker identification and the design of individualized therapies. Using chronic 
myeloid leukemia (CML) as a paradigm for hierarchical disease evolution we show that combined 
population dynamic modelling and CML patient biopsy genomic analysis enables patient stratification 
at unprecedented resolution. Linking CD34+ similarity as a disease progression marker to patient-
derived gene expression entropy separated established CML progression stages and uncovered 
additional heterogeneity within disease stages. Importantly, our patient data informed model enables 
quantitative approximation of individual patients’ disease history within chronic phase (CP) and 
significantly separates “early” from “late” CP. Our findings provide a novel rationale for personalized 
and genome-informed disease progression risk assessment that is independent and complementary to 
conventional measures of CML disease burden and prognosis.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent hematopoietic stem 
cell (HSC) and the first human cancer that was found associated with a single consistent and causative molecular 
alteration, the oncogenic fusion tyrosine kinase BCR-ABL. Expression of BCR-ABL results from a reciprocal 
chromosomal translocation [t9;22 (q34;q11)] giving rise to the Philadelphia chromosome containing BCR-ABL1, 
the fusion of the breakpoint cluster region (BCR) gene and the Abelson tyrosine kinase (ABL1). BCR-ABL 
expression, with its constitutively active tyrosine kinase activity, is sufficient for the transformation of HSCs lead-
ing to CML1. Aberrant BCR-ABL signalling relays via a network of signalling pathways, reprogramming cellular 
signalling throughout chronic phase (CP), ultimately leading to myeloid hyperplasia and progression into accel-
erated phase (AP) and blast crisis (BC), if left untreated2,3. Potent treatment regimens have been established, yet 
hematopoietic stem cell transplantation remains the only cure4. For all other therapies, better response rates are 
achieved the earlier the disease is diagnosed and treated5. Despite progress made in the treatment of CML with 
tyrosine kinase inhibitors (TKI) since the advent of imatinib (Gleevec®), advanced disease still poses a problem, 
with lower treatment success and elevated relapse rates6. Prevention of disease progression remains the primary 
goal, and prediction of progression risk is of high clinical relevance. While disease stage classification has been 
refined via clinical, morphological, and genetic markers, the prediction of individual CP patients’ progressing risk 
is difficult to assess, with progression remaining a risk despite TKI treatment7,8. Prognostic scores such as Sokal, 
Euro (“Hasford”) or EUTOS are widely used in CML patient care. Despite being valid prognostication and pre-
diction tools, these scores solely rely on established clinical parameters and still do not allow reliable inference of 
individual progression risk (Fig. 1a)9–11. Sokal and Euro scores were designed in the pre-imatinib era for improved 
1Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, 
Germany. 2Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of 
Medicine, RWTH Aachen University, 52074 Aachen, Germany. 3Paul O’Gorman Leukaemia Research Centre, Institute 
of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 0ZD, United 
Kingdom. 4Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 5Aachen Institute for Advanced Study 
in Computational Engineering Science (AICES), RWTH Aachen University, 52062 Aachen, Germany. *These authors 
contributed equally to this work. Correspondence and requests for materials should be addressed to A.S. (email: 
schuppert@aices.rwth-aachen.de)
Received: 28 October 2015
Accepted: 17 March 2016
Published: 06 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24057 | DOI: 10.1038/srep24057
comparison of clinical trial outcome. The Sokal score, however, has proven predictive for relapse-free survival 
after cessation of imatinib therapy, while the EUTOS was specifically developed to identify patients that do or 
do not benefit from imatinib12. Scores to predict failure of second generation TKIs, such as the “Hammersmith 
score”, have been developed and are in clinical use, despite limitations13.
Here, we focus on the need for novel biomarkers for individualized risk assessment. Dynamic CML progres-
sion modelling has largely been focussed on CP and the evolution of BCR-ABL ratios14,15. This allows only limited 
Figure 1. Analysis Workflow. Workflow outlining rationale and analytical pipeline. (a) Established clinical 
parameters classify CML patients in disease progression states regardless of genomic profile. (b) Combination 
of conventional scores, e.g. blast count, with patient gene expression (GEX) - derived genomic scores “CD34+ 
similarity” and “entropy” enables patient characterisation according to complementary scores at increased 
resolution. CD34+ similarity indicates disease history and progression risk, entropy is a quantitative measure 
of disorder or lack of GEX co-regulation. (c) Focus on CP patient progression risk assessment according to the 
CML population dynamic model by Dingli et al.15. The model parameter CD34 ratio reflects cell population 
dynamics and is correlated with patient CD34+ similarity scores. Non-monotonic evolution of the model 
parameter entropy serves as alignment marker to map patient gene expression and disease time within CP. 
CP = chronic phase, AP = advanced phase, BC = blast crisis of CML.
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assessment of gene expression changes within the cell types implicated in progression and is not predictive of 
progression to AP or BC. Dynamic simulations focussed on imatinib therapy provided functional insights into 
the dependence of imatinib efficacy on the proliferative status of BCR-ABL-positive HSCs16. Model development 
for disease classification of first encounter patients requires modelling in the untreated state. While this approach 
suffers from a lack of longitudinal data, clinical validation is mostly impossible, since patients are routinely sub-
jected to TKI treatment upon diagnosis. Therefore, despite statistical complications, utilization of retrospective 
datasets represents a supplementary approach. Gene expression profiling has enabled unsupervised analyses of 
progression stages17.Although recent results indicate a reliable patient characterization using supervised gene 
expression biomarker identification, they failed to show sufficient reliability for clinical use18. Still, genome-wide 
differential expression based biomarkers display a remarkable stability across heterogeneous studies of clinical 
samples19,20. Gene expression measurements will enter future CML diagnostic routine, as has been shown for 
breast cancer, where gene expression assays provide clinically useful prognostic information21.
To address clinical need of CML patient status and risk assessment with respect to disease evolutionary 
time, we evaluated the utilization of retrospective, non-longitudinal data from untreated patients to derive 
patient-specific genomic progression scores. We propose a novel approach to overcome statistical complications 
arising from supervised analysis of multivariate “omics” datasets and to address limitations of existing models. 
Figure 1 outlines the overall motivation and analytical strategy of our approach. In contrast to former strategies, 
our approach relies on the integration of an established CML population dynamic model with two patient-derived 
genomic biomarkers: firstly, a biopsy genome-wide expression-derived CD34+ similarity score as indicator of dis-
ease history and progression risk; and secondly, gene expression entropy as indicator of instability during criti-
cal states (Fig. 1b). The approach recapitulates patient classification according to established clinical stages and 
parameters. Also, our strategy reveals additional heterogeneities amongst CP patients and suggests a separation 
of “early” versus “late” CP, which lends itself to progression risk assessment.
In order to infer patient status from genomic profiles and CML population modelling, we combined scores 
obtained from an established model with the two corresponding patient-derived genomic scores17,15 (Fig. 1c). We 
calculated patients’ CD34+ similarity status, where expression of the differentiation marker CD34 is high in stem 
cells but lost during differentiation. The corresponding model parameter CD34 ratio reflects these cell population 
changes during CML hematopoiesis, where, over time, CD34+ blasts outnumber differentiated and committed 
CD34− cells. CD34 ratio is correlated with patient CD34+ similarity scores, connecting CP patient disease status 
with disease progression time in the model. Additionally, we considered entropy as a quantitative measure of dis-
order and gene expression de-regulation. The non-monotonic evolution features of modelled entropy served as 
an alignment marker to map patient gene expression and disease time. Here, we relied on the published time span 
of six years between the occurrence of the first CML HSC and clinical presentation of the disease as an established 
generalization in order to introduce our mapping concept15. Our integrated approach extends existing modelling 
concepts and addresses clinical need by enabling disease status approximation with respect to disease evolution-
ary time. Despite existing limitations, this relation of patient genomic status to disease time represents a method-
ological innovation in addition to conventional clinical scores that is not restricted to CML, but holds potential 
for predictive modelling in a variety of other malignant diseases with seemingly homogenous extended chronic 
phases, especially those with a risk of progression into lethal stages that are often unresponsive to treatment.
Results
Separation of population-based and mechanistic effects using stem and progenitor cell data 
from primary CML patients. Established computational models describing CML progression dynamics 
simulate disease evolution in terms of hematopoietic population growth over time15,16. To directly assess CML 
disease stages with respect to disease evolutionary time, we aimed at reconciling patient gene expression with 
an established model of CML evolution by Dingli and co-workers (Supplementary Resources and Methods)15. 
First, to investigate the degree to which CML progression is driven by hematopoietic cell population dynamics 
as opposed to differences in the genetic underpinnings of respective disease stages, we analysed GEO dataset 
GSE47927, comprising data obtained from CD34+ enriched, flow sorted CML stem and progenitor cell pop-
ulations from 12 CML patients, of which six CP, four AP, and two BC, versus matching populations from three 
healthy volunteers (Supplementary Resources and Methods)22. We visualized gene expression patterns by prin-
cipal component analysis (PCA) considering the information-rich subset of the human genome of ~6,000 genes 
with high predictive accuracy regarding clinical phenotypes and stable biomarkers during meta-analysis of clin-
ical data sets20 (Methods). The first three PCs revealed differential expression, clearly separating HSCs, com-
mon myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), and megakaryocyte-erythroid 
progenitors (MEPs) (Fig. 2, Supplementary Fig. S1). CML HSCs display an increase along PC2 compared to 
normal HSCs. This clear separation between CML and normal HSCs along PC2 is less pronounced for normal 
versus CML CMPs, and is not apparent in GMPs or MEPs, indicating that differential gene expression, evident 
by separation along PC2, decreases with hematopoietic differentiation. Up-regulated genes in PC2 include CSF1, 
CSF2RB, CD38, CD36, and FCGR2A, and down-regulated genes include CD34 and CD79B, suggesting that CML 
HSCs are phenotypically more differentiated towards the myeloid lineage than normal counterparts. PC1 and 
PC2 parameters are therefore able to detect BCR-ABL - induced changes in HSCs. Comparing these trends to a 
projection of the gene expression from clinical samples of patients in different CML disease stages (dataset GSE 
4170)17 suggests that genome-wide differential expression in CML is driven by population- based differentiation 
processes rather than mechanistic effects linked to disease progression (Supplementary Fig. S2).
Discerning CML disease stages by CD34 status of patient gene expression. We hypothesized 
that gene expression associated with differentiation could serve as an indicator of hematopoietic cell population 
changes associated with CML progression. During healthy hematopoiesis, the surface marker CD34 distinguishes 
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immature HSCs and progenitor populations (CD34+) from committed precursors and differentiated cells 
(CD34−). An expansion of CD34+ immature blasts is a hallmark of CML progression23,24. The increase of imma-
ture CD34+ over differentiated CD34− cell populations entails an increasing CD34 ratio with disease progression. 
We inferred the CD34 ratio according to equation (1), as a corresponding model parameter from an established 
model of multi-compartmental hematopoiesis15. Since CD34 ratio increases over time in accordance with this 
model, we hypothesized that we can use it to link patient status, examined at hand of patient-specific CD34 
expression scores, in order to map patients to CML disease time in the model.
We assessed CD34 expression in mixed-population clinical samples of CP (42), AP (9), APcyto (8), and BC (28) 
patients (dataset GSE4170)17 to obtain CD34+ similarity scores as a corresponding patient parameter and indica-
tor of disease status (Supplementary Resources and Methods). CD34+ similarity scores represent hematopoietic 
differentiation status over time in healthy individuals and CML patients. Combining patient-derived genomic 
information with the conventional parameter blast count, we show that CD34+ similarity adds an additional 
dimension of separation of established CML stages. While separating CP from advanced stages (AP, BC), blast 
count alone does not distinguish CP cases amongst each other, or from APcyto cases, which are characterized by 
additional cytogenetic changes only. CD34+ similarity, however, separates CP, APcyto, AP and BC cases, indicating 
increasing similarity of patient gene expression to CD34+ naïve cells with disease progression, and distributes 
CP patients over more than one order of magnitude, suggesting differences during CP evolution that are not 
resolved by blast count alone (Fig. 3a). Importantly, patient CD34+ similarity scores correlate significantly with 
model-derived CD34 ratios (R2 = 0.934, p = 3e-25) (Supplementary Fig. S3). This correlation represents a mono-
tonic map between disease progression time in patients and in the model, which we assume to be linear in CP. 
Since the parameters are not known a priori, a second progression marker is required, whose dynamics are not 
correlated and as such independent of the first marker, CD34 status.
Entropy of gene expression as indicator of disease progression. We assessed Shannon entropy 
according to equation (2) as a quantitative measure of the disorder and lack of co-regulation of gene expres-
sion. Simulated entropy of randomized gene expression displays a non-monotonic dynamic trend with a singular 
minimum. Equally, simulated entropy of cell population mixing throughout hematopoietic evolution (mixing 
entropy) shows a singular maximum aligning with the minimum of simulated entropy. We conclude that lowest 
gene expression entropy coincides with highest heterogeneity of cell populations (cell population mixing effect), 
whereas entropy is higher for homogeneous cell types (Supplementary Fig. S4, Methods). We therefore consider 
low gene expression entropy as an indicator of population heterogeneity, instability, and disease progression. 
Both entropies are related to the time scale of disease evolution in the model. Comparing patient-derived and 
simulated entropies, we find significant correlation (p = 0.0195). Challenging the significance of this correlation 
through random sub-sampling reveals a frequency distribution with p values < 0.05 for a majority of 80.2% of 
iterations (Supplementary Fig. S5). Next, we assessed patient gene expression (GSE4170) entropy in combination 
with CD34+ similarity in order to combine resolution provided by both markers. Compared to the separation of 
CML disease stages by CD34+ similarity and blast counts, entropy reveals further differences, especially amongst 
CP cases, with high entropy variability over the same CD34+ similarity range (Fig. 3b). We observe a V-shape in 
patient distribution as a result of two trends: with increasing CD34+ similarity, early CP cases show decreasing 
entropy, then entropy starts to incline again. Second, continued entropy increase with increasing CD34+ similar-
ities corresponds to progression into AP and BC. We find that AP and APcyto entropies are overall elevated and 
that BC entropy is increased with respect to CP, indicating loss of genome-wide gene expression regulation along 
progression. Advanced CML is located to the right side of the entropy minimum, AP patients starting to emerge 
first, followed by BC patients. We conclude that AP cannot be described by mere mixing of CP and BC, but that 
it rather represents an intermediate stage with characteristic expression features17. Four putative CP outliers at 
entropy > 2 are in CD34+ neighbourhood of some APcyto cases. Entropy > 2 is characteristic for eight out of nine 
Figure 2. Separation of population-based and mechanistic effects using stem and progenitor cell data 
from primary CML patients. Genome-wide gene expression of 4 stem- and progenitor cell subpopulations 
(colours) across all phases of CML progression (shapes) in 12 patients and three healthy controls, represented 
by PCA-derived components 1, 2, and 3. PC: Principle Component, CP: chronic phase, AP: accelerated phase 
(by blast count criteria), APcyto: accelerated phase (by occurrence of additional clonal cytogenetic changes 
without increase in blast count), BC: blast crisis, HSC: hematopoietic stem cell, MEP: megakaryocyte-erythroid 
progenitor, GMP: granulocyte-macrophage progenitor, CMP: common myeloid progenitor. Data from GEO 
dataset GSE47927, by Copland M and Irvine DA22.
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APcyto cases, whereas the majority of CP cases have entropies < 2. We hypothesized that these CP cases represent 
early APcyto patients not classified as such by conventional methods. Comparing their gene expression against 
CP cases in the same CD34+ similarity range albeit with lower entropy (< 2), we found significant differential 
expression (p-value < 0.01, FDR-adjusted p-value), whereas comparison to APcyto samples in the same range 
did not reveal significant differences (p > 0.01), supporting their similarity by genomic features. Since these p 
values are based on the present patient cohort only, they should be considered as indicators. Positioning along the 
entropy axis identified a sub-population of CP patients as putative “early” APcyto cases with signs of early onset of 
disease progression.
Assessing CP CML status and progression risk. To address the challenge of disease status identification 
and progression risk prediction during CP CML, we turned to the mapping of CP patient status to disease pro-
gression time15. Since gene expression entropy is directly related to CML evolutionary time through the model, 
we used the non-monotonic evolution features of entropy as an alignment marker to map patient gene expres-
sion and disease time (Fig. 1c). Entropy introduces a significant V-shape (p = 0.014788, linear regression) within 
CP samples when distributed along CD34+ similarity (Fig. 4a, Methods). To match model and patient data, we 
normalized CD34+ similarity scores and the CD34 ratio to the interval [0, 1] to highlight similarity of entropy 
evolution between clinical data and model simulation (Fig. 4a, Supplementary Fig. S6). Since CD34+ similar-
ity corresponds to CD34 ratio, and therefore to disease time according to the model, we mapped normalized 
‘observed entropy – simulated entropy’ pairs to a time interval of ~6 years (2,200 days) as a general approximation 
to the average disease behaviour across a heterogeneous patient population, and in accordance with the mod-
elled duration from the initiating mutation until diagnosis (equation (3)). In order to align the minima observed 
in patient gene expression entropy and in simulated entropy, we pinned corresponding data points by finding 
minimum entropy distance between each pair (Fig. 4b, Supplementary Fig. S6, Methods). Herein, we present an 
integrated modelling strategy for the translation of clinical stage to true time scale of disease evolution, leveraging 
the combined power of CD34 status and entropy parameters.
We hypothesized that differences between CP patients resolved by CD34+ similarity and entropy could indi-
cate an early disease progression trajectory. Following normalization and patient mapping to model-derived dis-
ease evolutionary time, we considered the simulated entropy minimum singularity as an indicator for a critical 
disease state transition during CP and separated “early” (T1) from “late” (T2) CP patients at the entropy minimum 
Figure 3. Integrated tracking of CML disease progression stages from mixed-population clinical samples. 
(a) Data points represent clinical samples of 42 CP (green), 9 AP (blue), 8 APcyto (purple), and 28 BC (red) 
patients17. Each asterisk represents one patient. Differences between patients and corresponding disease stages 
are resolved by CD34+ similarity score in combination with blast count. (b) Data points as in a. Entropy of 
patient gene expression resolves differences in disease stages in combination with CD34+ similarity score.
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borderline at t = 1476 days, corresponding to ~4.04 years and a CD34+ similarity score ~0.403 (un-normalized 
score = 13.34) (Fig. 5a). While patient CD34+ status is assessed from genomic data, the corresponding 4-year 
time interval is restricted to the model parameters. This time point is directly dependent on calculation of the 
CD34 ratio at the exemplary cut-off at compartment 23, from which committed precursor cell types dominate 
over undifferentiated progenitors according to the multi-compartment model25. Testing the impact of param-
eter variations on this boundary, we calculated CD34 ratios across all possible cut-offs for CD34+ expression 
and observed a robust T1–T2 boundary around 4 years (Supplementary Fig. S7, Supplementary Resources and 
Methods).
Genomic differences confirm early disease progression during CP CML. We next assessed differ-
ential expression between the thirty-four T1 and eight T2 CP patients and identified 411 differentially expressed 
genes (FDR-adjusted p-value < 0.05), indicating that T1 and T2 CP differ by differential expression of almost 10% 
of genes, compared to ~20% when comparing AP vs. BC (Fig. 5b, Supplementary Fig. S8). The ratio of differential 
genes between T1-CP and AP (66.8%) is > 2-fold increased compared to T2-CP and AP (32.3%), clearly distin-
guishing T1-CP and T2-CP with respect to progression towards AP, and highlighting the significance of the two 
groups in terms of disease progression within CP. This difference is upheld when compared against BC patients. 
T1-CP and BC differ by differential expression of 80.7% of genes, compared to 46.14% between T2-CP and BC. 
These unexpected, profound effects within CP suggest that T2-CP may represent a higher risk state with respect 
to progression. We confirmed robustness of these substantial fractions with respect to changes in cohort size by 
random sub-sampling analysis (Supplementary Figs. S9 and S10, Supplementary Resources and Methods).
Assessing differences in biological processes by Gene Ontology (GO) enrichment amongst the 411 genes 
differentially expressed between T1- and T2-CP, we found 91 biological processes significantly enriched for 
down-regulated genes, and 228 terms for up-regulated genes. While GO terms enriched amongst up-regulated 
and down-regulated genes overlap with 65 common terms, 26 processes were exclusive to down-regulated genes, 
and 163 were exclusive to up-regulated genes (Supplementary Tables S1 and S2). Several processes frequently 
observed amongst both up- and down-regulated genes are represented at approximately equal proportions, such 
as terms related to protein translation, modification or trafficking (15% in up- vs. 12% in down-regulated genes), 
and metabolism, biosynthesis or catabolic processes (11% vs. 10%, respectively). Strikingly, 31% of GO biological 
Figure 4. Assessment of CP patient disease status and progression risk. (a) Data points represent clinical 
samples of 42 CP patients (green asterisks) (GSE4170, Radich et al. 2006a). Normalized CD34+ similarity score 
combined with entropy of patient gene expression and simulated entropy maps CP evolutionary time intervals 
between model and patients. (b) 42 CP patients (green asterisks) as in a. plotted by observed entropy from 
clinical gene expression data and simulated entropy from the model converted to time (days after initial HSC 
mutation). Timespan covers ~6 years in accordance with the model.
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processes exclusively enriched amongst down-regulated genes pertain to innate immune response regulation, 
while no GO process of this category is enriched in the jointly differentially regulated set or amongst up-regulated 
genes. Also, 15% of processes exclusively enriched amongst down-regulated genes are related to cellular differen-
tiation and development. On the other hand, 13% of GO terms enriched exclusively amongst up-regulated genes 
are related to signal transduction involved in DNA damage, integrity checkpoints or general cell cycle control. 
These over-representations are in concordance with cancerogenic processes, including innate immune responses 
to changes in tissue homeostasis, impaired cellular differentiation, and DNA damage response signalling upon 
genomic instability, underlining the significance of the progression trend between T1- and T2-CP26–28.
Discussion
CML represents a targeted cancer therapy paradigm and served as foundation for the first computational models 
providing insights into in vivo kinetic behaviour of a human cancer. In CML, BCR-ABL alone induces a mono-
clonal malignancy with a strong phenotype. Tumour cells remain dependent on BCR-ABL and can be forced into 
apoptosis by targeted inhibition with TKIs such as imatinib, while CML HSCs appear insensitive29,30. Pioneering 
computational modelling of CML kinetics during imatinib therapy revealed a biphasic exponential decline of 
leukemic cells, where the first slope corresponds to differentiated cells and the second slope to leukemic progeni-
tors, suggesting that leukemic HSCs are not depleted14,31. This model is challenged by evidence based on outcome 
of CML patients undergoing imatinib mono-therapy, according to which long-term clinical response data are 
consistent with models considering a primary imatinib effect on proliferating BCR-ABL1-positive HSCs, when 
committed into the cell cycle16,32. These studies highlight the importance of competition between normal and 
leukemic cells for CML therapy33. Recent evidence corroborates that CML cells outnumber normal cells, promot-
ing proliferation, altering differentiation, and inhibiting self-renewal capacity of non-transformed progenitors 
via interleukin 6 34. Even though competition effects ought to aggravate the differentiation block, exacerbating 
the CD34 ratio shift, our model may underestimate the effect of CML cells, as the data we considered lacks a 
separation of healthy vs. CML cells. Our approach suffers from the limitation that competition effects cannot be 
considered. Also, we cannot address heterogeneity introduced through diverging mutational patient profiles or 
varying proliferation rates. While intrinsic model time can at most address an average patient population, our 
approach uses individual progression scores to match patients to the model, leaving classification results unaf-
fected by patient variation in proliferation rate. Leukemias are considered less complex regarding the number of 
mutations compared to the majority of solid tumours35. Therefore, despite these limitations and controversies, 
Figure 5. Entropy-based separation of early vs. late chronic phase (CP) patients. (a) Integrating CD34+ 
similarity score with entropy of patient gene expression and simulated entropy resolves differences in patient 
disease evolutionary time. 42 CP patients (asterisks) plotted by observed entropy from clinical gene expression 
data aligned by model-derived simulated entropy converted to disease time span (days). Time span covers ~6 
years in accordance with the model. The red borderline separates “early” (T1) from “late” (T2) CP patients (light 
and dark green asterisks, respectively) at the simulated entropy minimum singularity at t = 1476 days (~4.04 
years), and CD34+ similarity score = 0.403. b. T1 and T2 CP patient groups are significantly different in terms 
of gene expression (T1 vs. T2, FDR-adjusted p < 0.05). Progression towards advanced stage is highlighted by 
increasing differential gene expression compared to AP and BC, where the fraction of differentially expressed 
genes of T1-CP vs. AP (66.8%) > T2-CP vs. AP (32.3%), and T1-CP vs. BC (80.7%) > T2-CP vs. BC (46.14%).
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CML represents a suitable model disease, especially useful for the development of predictive models aimed at 
clinical translation.
To date, CML models have either focused on the simulation of generic disease progression within CP under 
therapy, or on characterizing individual patients’ progression. Despite advancements in CML treatment, fun-
damental challenges in disease management remain. Following a homogenous and extended CP, a minority of 
patients evolve more aggressive myeloid neoplasia with lower drug response and higher relapse rates5,36. Even 
during TKI therapy, patients are at risk of disease progression, predominantly during the first two years37, suggest-
ing that affected patients may have been diagnosed in “late” CP. Accelerated telomere shortening has been pro-
posed as a prognostic CML marker38,26. While this process might be attributed to an inflammatory environment39, 
as shown for other malignant diseases40, we did not observe increasing inflammatory gene expression during CP 
progression. Gene expression data from unsorted, bone marrow - derived CML cells challenged the three-phase 
progression concept, suggesting that AP may not represent a discrete stage17, whereas our results support the 
concept that AP represents a transition state. Considering CML dynamics we conclude that precise, personalized 
staging and risk assessment based on genomic and molecular parameters should inform clinical strategy. The 
need for precise staging within CP remains a core issue of clinical relevance. How long has the disease persisted 
prior to diagnosis? What is the patient’s time from transition into advanced disease?
To this end we present a novel approach for characterization of patient status along disease evolutionary time. 
Firstly, our focus on CP is justified by the availability of population dynamic models, higher therapeutic success 
rates, and the need to prevent progression. Within clinically homogenous stages, identification of appropriate 
parameters to assess disease evolution is not straightforward. Secondly, our integrated approach addresses this 
shortcoming and aims to improve predictive modelling. We show that CD34+ similarity scores achieve patient 
separation along CML progression, revealing differences within CP that are not resolved by blast count alone. We 
observed linear correlation between patient-derived CD34+ similarity and CD34 ratio, the corresponding model 
parameter. Motivated by the concept of phase transitions of complex systems in statistical thermodynamics41, we 
assessed Shannon entropy of gene expression to reveal critical states that can connect patient status and model 
disease over time. We observed characteristic entropy singularities, where low gene expression entropy relates to 
high cell population heterogeneity, instability, and disease progression, indicating that quantitative concepts from 
phase transition theory can be utilized as complementary factors in biomedicine for the development of quanti-
tative disease models. We introduced entropy as an alignment marker to retrospectively match CP CML patient 
status to model disease progression time (“pinning”)17. Both markers, CD34 status and entropy, are strictly com-
plementary, together achieving a new level of resolution for genome-informed patient stratification. Quantifying 
patient fractions within disease stages throughout both dimensions enables estimation of disease stage likelihood 
(Fig. 6a). This quantification recapitulates the established progression trajectory from CP via AP to BC, and 
highlights differences not revealed at the cellular level alone. While ~90% of patients are in CP at low CD34+ 
similarity, this fraction decreases to 60% with concomitant rise of ~40% in APcyto at the same CD34+ similarity 
and high entropy. These disease stage fractions are not observed by chance. Analogous and randomly staged 
patient cohorts would suggest about 40–50% CP, 10% AP, and 30–40% BC are in the first CD34+ similarity quar-
ter at low entropy. In reality, however, 90% of patients are in CP, and no patients are in AP or BC in the clinical 
cohort. (Supplementary Fig. S11). The second quarter marks a low entropy phase, indicative of a transition state. 
In the third, CP is found less frequently than expected randomly, and more patients than expected by chance are 
annotated as AP. High entropy and high CD34+ similarity scores characterize 100% patients as BC, whereas only 
30–40% are expected by chance. This quantification lends itself as supporting rationale for genomics-based risk 
assessment in CML.
In summary, our approach i) relates patient status to disease time scale inferred from a population dynamic 
model, ii) provides a new way to approximate progression risk, and iii) reveals new insights into pathophysi-
ological CML dynamics. Entropy dynamics suggested a clear subdivision of CP into early (T1) and late (T2) 
stages with significant gene expression differences compared to advanced disease. Functionally, GO enrichment 
revealed broad genomic differential expression across hundreds of biological processes, pointing towards system-
atic changes during CML progression in consequence of BCR-ABL signalling, rather than deregulation of a single 
or defined set of signalling pathways. Enrichment of innate immune response processes amongst down-regulated 
genes points towards a compromised immune response and impaired tumour surveillance. While innate immu-
nity lacks the adaptive response’s antigen recognition, natural killer cells can target and eliminate cancer cells; a 
possible target mechanism for cancer immunotherapy42. Down-regulation of differentiation and development 
genes indicates impaired hematopoietic differentiation implicated in proliferative advantages of transformed 
cells. Enrichment in up-regulation of DNA damage, integrity checkpoint and cell cycle processes is indicative of 
responses to enhanced DNA damage and genomic instability, both implicated in disease progression and drug 
resistance36. Overall, reduced immune surveillance, impaired differentiation, and exacerbated genomic instability 
are hallmarks of cancer, reflected here by differential expression between two CP sub-groups.
We suggest that a normalized CD34+ similarity of ~0.4, or an interval of ~4 years from the initiating mutation, 
represents a risk point for disease progression. While patient CD34+ similarity status can be assessed directly 
from patient genomic data, the corresponding 4-year time interval is an approximation restricted to the model. 
As evidence and established models suggest ~3.5 to 6 years for the disease to become clinically apparent, our 
data lead us to conclude that after ~4 years CML enters an advanced stage of CP. Patients staged beyond this 
point could be subject to increased progression risk (Fig. 6b). Taken together, our model enables quantitative 
interpretation of a combination of conventional and genomic markers in terms of disease evolutionary time. Our 
observations establish direct links between patient gene expression and the underlying hematopoietic popula-
tion heterogeneity, positioning our approach as a novel exploratory tool with potential for wide applicability in 
clinical research. This potential extends not only to the complete spectrum of CML stages, but also to localized 
and metastatic solid tumours, other leukemias, or serious, malignant diseases with chronic stages at risk of fatal 
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progression, such as certain myeloproliferative neoplasms, where no mathematical models or predictive biomark-
ers exist to date.
Methods
Data Source and Preparation. To study hematopoietic cell population-based effects during CML disease 
progression we analysed GEO dataset GSE47927, comprising gene expression data obtained from four CD34+ 
enriched and flow sorted CML stem and progenitor cell subpopulations (HSC: hematopoietic stem cell, MEP: 
megakaryocyte-erythroid progenitor, GMP: granulocyte-macrophage progenitor, CMP: common myeloid pro-
genitor) across all phases of CML progression (CP: chronic phase, AP: accelerated phase (blast count), APcyto: 
accelerated phase (additional clonal cytogenetic changes without increased blast count), BC: blast crisis) from 
12 patients, of which six CP, four AP, and two BC, versus matching populations from three healthy volunteers22. 
For the identification of features associated with genetic underpinnings and mechanistic effects of disease pro-
gression, we used GEO dataset GSE4170 involving genome-wide gene expression data from 42 CML patients 
in CP, 9 in AP, 8 in APcyto, and 28 in BC17. CP patients with missing blast count information were assigned 
blast count = 1. Four BC patients with missing blast count information were not considered in the analysis. For 
principal component analyses using the gene expression datasets above, we started with a subset of the human 
genome of 6,384 genes that are characterized as information-rich by a low information ratio (IR), corresponding 
Figure 6. Integrated concept for CML patient stratification and risk assessment during chronic phase (CP). 
(a) Disease stage fractions (%) observed when patients are subdivided into CD34+ similarity quarters and low vs. 
high entropy, yielding eight sub-spaces. Graph represents disease stage fraction of each sub-space compared to all 
patients (42 CP (green), 9 AP (blue), 8 APcyto (purple), and 28 BC (red) patients17, as in Fig. 3). (b) CML patient 
biopsy gene expression profiling enables differentiation of patients by CD34+ similarity and gene expression 
entropy. A population dynamic model for quantification of the evolution of hematopoietic cell types across 
CML serves to identify dynamics that are characteristic for disease status. Upon entropy-mediated alignment 
to time scale of disease evolution during CP, patient status can be matched to disease evolutionary time for risk 
assessment and personalized therapeutic intervention.
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to predictive accuracy with respect to clinical phenotypes and stable biomarkers20. We then considered the sub-
set of low-IR genes represented as complete cases in the respective gene expression datasets, which are 6,078 
genes for dataset GSE47927, and 4,309 genes for GSE4170. All computations were performed in MATLAB (The 
Mathworks Inc, Version 14, Statistics Toolbox). For further details on the associated GEO datasets please refer to 
the Supplementary Resources and Methods.
Calculating CD34+ similarity scores from patient gene expression data. We calculated CD34+ 
similarity scores from patient data17 using the PhysioSpace method as described43. Briefly, we assembled a CD34+ 
reference by calculating mean gene expression over all CD34+ samples obtained from published dataset GSE4170. 
For this reference sample we then ranked the genes according to their expression level and extracted the top 
5% most up- and down-regulated genes as representative CD34+ status associated genes. We then calculated 
the CD34+ similarity score of each sample as signed log10-p-value obtained from Wilcoxon rank sum testing 
between the top 5% up- and down-regulated CD34+ status associated genes.
Modelling CD34 ratio. The population dynamic model by Dingli and co-workers considers hematopoiesis 
as a hierarchically structured process comprising 32 compartments25,15. During healthy hematopoiesis, stem cells 
(HSCs), progenitor and some precursor cells express CD34 surface marker (CD34+), while some precursors and 
terminally differentiated cells lose CD34 expression, and mature cells representing the majority of the hemato-
poietic cell mass are CD34−. During CML, however, a differentiation block causes population shifts to a highly 
abundant pool of CD34+ leukemic blasts, shifting the ratio of CD34+/CD34− (CD34 ratio). This increase in CD34 
ratio can be inferred according to the model by Dingli et al. as follows:
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In order to integrate CD34+ similarity scores derived from patient gene expression data17 with the CD34 ratio 
obtained from the mechanistic model into a unique variable, we assume linear correlation through a monotoni-
cally increasing function.
Assessing patient biopsy genome-wide expression entropy. In order to calculate the Shannon- 
entropy for each patient sample k according to:
∫= −S p x p x( )log ( ) (2)k k k
we used original data from17 to calculate the distribution density p(xk) in sample k for the information-rich subset 
of ~6,000 genes of the human genome that are characterized by a low information ratio (IR)20. We assessed the 
V-shape resulting from entropy differences as a dependent variable with respect to CD34+ similarity as an inde-
pendent variable in CP CML patients using linear regression modelling using the ‘fitlm’ function with quadratic 
term (MATLAB Linear Regression Package).
Model-based simulation of gene expression entropy. To calculate the simulated gene expression 
entropy based on the population dynamic model15, we generated a randomly simulated gene expression matrix 
SGEM such that the number of rows is equal to 64, as we consider each 32 compartments of healthy and CML 
cells. The number of columns is identical to the number of genes (6,384 low IR genes) considered from patient 
gene expression data. Rows represent expression of the ~6,000 genes in each cell population (compartment). In 
order to simulate the gene expression dynamics of a mixed population of cell types, we weighted each gene in 
the SGEM according to the cell population dynamics during CML evolution in CP, which were inferred from the 
population dynamic model. We thereby obtained expression changes of each gene in a mixture of healthy and 
CML cells during CP evolution. We calculated the simulated gene expression entropy as Shannon-entropy of this 
final product (st).
Mapping clinical data to time scale of disease evolution for CP patient disease progression 
risk assessment and stratification. In order to match patient samples to time of disease progression we 
aligned entropy profiles derived from model simulations and patient gene expression, considering CD34 ratio to 
be a surrogate for time, as follows:
≅CD CD t years[min( 34 ), max( 34 )] [ , 6 ] (3)Ratio Ratio 0
Second, we independently normalized patient-derived CD34+ similarity score and simulated CD34 ratio to 
the same interval [0 1]. Then, considering linear correlation between CD34 ratio and CD34+ similarity score 
(Supplementary Fig. S3), we observed similarities in evolution of entropy derived from patient gene expression 
compared to simulated entropy (Fig. 4a). This normalization enabled mapping of CP CML patient samples within 
the time scale of disease evolution in a quantitative way.
In order to perform this mapping we first identified the corresponding CD34 ratio for each individual patient 
by calculating the distance between each patient’s normalized CD34+ similarity score and all possible normalized 
CD34 ratios. We then identified the nearest simulated entropy point in order to obtain pairs of minimum distance 
between observed (patients) and simulated entropy (model). Since each CD34 ratio is equivalent to a unique 
time point according to the model, we obtain a corresponding time point for each patient. Thereby we aligned 
both minima of simulated and patient – derived entropies (“pinning”), such that each CP patient is at minimum 
distance to its corresponding simulated data point in both independent scores (Fig. 4b).
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Analysis of differential expression along disease progression stages. To assess differential gene 
expression patterns between disease stages we considered the set of 4,309 genes represented as complete cases in 
dataset GSE4170 that were also amongst the 6,384 genes with low information ratio (IR) as described20. A cut-off 
of p < 0.05 (FDR-adjusted p-value) was used to identify differentially expressed genes between two groups. 
Significance of differential expression was assessed by 2-sided t-test (MATLAB statistical toolbox).
Gene Ontology enrichment analysis. Gene Ontology (GO) enrichment analysis was performed on each 
set of significantly differentially up- or down-regulated genes between early (T1) and late (T2) CP. Since analy-
sis of differential gene expression was performed by 2-sided t-test, the differences between the mean of T1-CP 
and T2-CP distributions classified each gene as up- or down-regulated. GO enrichment analysis was carried 
out according to the PANTHER Overrepresentation Test (release 20150430) against the reference set of 4,309 
genes from dataset GSE4170 that were represented amongst the 6,384 genes with low information ratio (IR) (see 
above)20, considering the GO Ontology database released 2015-08-06, including Bonferroni correction for multi-
ple testing. Biological processes with p < 0.05 were considered and ordered by fold enrichment.
Disease stage quantification and patient cohort randomization control. In order to quantify how 
CML disease stages (CP, APcyto, AP, and BC) partition amongst the patient cohort, CD34+ similarity and gene 
expression entropy ranges were evenly divided into quarters and halves (low vs. high entropy), respectively, divid-
ing the CD34+ similarity – entropy area into eight rectangular subsets. For each subset, we calculated the ratio 
of patient count per disease stage over the total number of patients in the cohort in order to obtain the fraction 
for each disease stage per subset. We performed cohort randomization controls to assess the significance of the 
observed distributions. New disease stage annotations were randomly assigned 1,000 times to each of the 92 
patients, maintaining the overall patient distribution and only changing disease stage annotation. Random sam-
pling permutation was carried out using the MATLAB random sampling tool (The Mathworks Inc, Version 14, 
Statistics Toolbox). Disease stage fraction distribution was analysed for each of the 1,000 random patient cohorts 
as described above. Results are presented as histograms of frequency over fraction (%). Actual fractions observed 
in the patient cohort (GSE4170) are indicated (red lines) (Supplementary Fig. S11).
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